FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Iohexol (Omnipaque) Injection
Status: Currently in Shortage
»Date first posted: 05/09/2022
»Therapeutic Categories: Medical Imaging

Expand all

GE Healthcare (Revised 05/20/2022)

Company Contact Information:
800-292-8514

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
NDC (0407-1413-68), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-94), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-25), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-98), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-72),300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-72), 350 mg/1 mL INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-89), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-88), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-48), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-48), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1415-09), 9 mg/1 mL, SOLUTION, ORAL Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1416-12), 12 mg/1 mL, SOLUTION, ORAL Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-014-10), 388.3 mg/1 mL, SOLUTION,IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-014-12), 388.3 mg/1 mL, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-014-15), 388.3 mg/1 mL, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-017-10), 518 mg/1 mL, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-017-12), 518 mg/1 mL, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-017-15), 518 mg/1 mL, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-020-10), 647.1 mg/1 mL, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-020-12), 647.1 mg/1 mL, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (42852-020-15), 647.1 mg/1 mL, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-10), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-20), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-27), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-28), 240 mg/1 mL,INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-29), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-30), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-33), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-34), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-35), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-49), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-50), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-60), 240 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-10), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-11), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-30), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-50), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-51), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-53), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-59), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-60), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-61), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-62), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-63), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-65), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-66), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-69), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-90), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-91), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-92, 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-93), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-95), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-96), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-98), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-99), 300 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-03), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-04), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-20), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-21), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-22), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-23), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-24), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-50), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-51), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-52), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-53), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-60), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-76), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-80), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-89), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-90), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-91), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-93), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-94), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-95), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1401-52), 140 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1411-10), 180 mg/1 mL, INJECTION, SOLUTION, ORAL Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1411-20), 180 mg/1 mL, INJECTION, SOLUTION, ORAL Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-38), 240 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-39), 240 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-40), 240 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1412-84), 240 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-41), 300 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-42), 300 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-43), 300 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-46), 300 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-47), 300 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-86), 300 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-87), 300 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1413-88), 300 mg/1 mL, INJECTION, SOLUTION, IT Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-41), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-42), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-43), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-44), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-45), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-82), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-84), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-85), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-86), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other
NDC (0407-1414-87), 350 mg/1 mL, INJECTION, SOLUTION, IV Partial supply/backordered. Anticipate full stock by July 2022. Impacted by Covid-related shutdown in China; supply increasing through May and June with a return to stocking levels in July 2022; https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Iohexol%20(Omnipaque)%20Injection&st=c

GE Availability Update

Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English